Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Gastric Carcinoma: early-phase trial registry

5 of 9 indexed Gastric Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Gastric Carcinoma: 9 US clinical trials tracked, 5 recruiting.

Gastric Carcinoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Jonsson Comprehensive Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition gastric-carcinoma

OPEN 5 | RECR 56% | LATE 0 | EARLY 3 | RANK #1916 | SPON 2

Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)

Gastric Carcinoma (this)56%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Gastric Carcinoma

Gastric Carcinoma lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Gastric Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Gastric Carcinoma is recruiting above its size-band peers.

    5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Gastric Carcinoma research.

    Jonsson Comprehensive Cancer Center accounts for 2 of 9 trials (22.2%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Gastric Carcinoma enrolment sits around 66 participants.

    Median target enrolment is 66 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Gastric Carcinoma research is mostly interventional.

    7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13

Open and recent trials

9 total, page 1 of 1

RECRUITING NA 24,000 participants

The Vanguard Study: Testing a New Way to Screen for Cancer

National Cancer Institute (NCI)

NCT06995898

RECRUITING 1,600 participants

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

NCT04314401

RECRUITING NA 240 participants

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

City of Hope Medical Center

NCT06408220

RECRUITING Phase 1 135 participants

A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

Boehringer Ingelheim

NCT06882746

RECRUITING Phase 1 30 participants

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

NCT07118176

ACTIVE NOT RECRUITING NA 53 participants

Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery

City of Hope Medical Center

NCT05203627

ACTIVE NOT RECRUITING Early Phase 1 29 participants

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Jonsson Comprehensive Cancer Center

NCT04147494

COMPLETED NA 66 participants

The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer

Ohio State University Comprehensive Cancer Center

NCT04602026

COMPLETED 24 participants

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

M.D. Anderson Cancer Center

NCT05083338

Phase Distribution

PhaseTrial count
Phase 1 3

Named interventions

Most-linked intervention names on Gastric Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
4 trials
Biospecimen Collection Procedure
4 trials
Computed Tomography Procedure
3 trials
Gallium Ga 68 FAPi-46 Radiation
2 trials
Best Practice Other
2 trials
Positron Emission Tomography Procedure
2 trials
Pain Assessment Procedure
1 trials
18F-FDG Radiation
1 trials

US sites by state

Facility locations filed on Gastric Carcinoma trials. A trial with sites in several states counts in each.

California 7 trials
Colorado 2 trials
Texas 1 trials
Ohio 1 trials
New Jersey 1 trials
Michigan 1 trials
Hawaii 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Gastric Carcinoma page

9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastric Carcinoma condition card totals 9 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.